SLC2A1 and metabolic disease: It promotes glucose uptake by directly upregulating GLUT1/3, promotes glycolysis by upregulating hexokinase 2 (HK2), and promotes lipogenesis by directly interacting with SREBP.111 Therefore, abnormal Hippo/YAP pathways may be the potential pathogenesis of IR and other metabolic disease (Fig. 2i).